Skip to content
Recarbrio(relebactam)
Recarbrio (relebactam) is a small molecule pharmaceutical. Relebactam was first approved as Recarbrio on 2019-07-16. It is used to treat intraabdominal infections, pyelonephritis, and urinary tract infections in the USA. It has been approved in Europe to treat gram-negative bacterial infections.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
Trade Name
FDA
EMA
Combinations
Recarbrio
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cilastatin sodium
+
Imipenem
+
Relebactam
Tradename
Company
Number
Date
Products
RECARBRIOMerck Sharp & DohmeN-212819 RX2019-07-16
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
recarbrioNew Drug Application2021-04-09
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
intraabdominal infections—D059413—
pyelonephritisEFO_1001141D011704N10-N16
urinary tract infectionsEFO_0003103D014552N39.0
Agency Specific
FDA
EMA
Expiration
Code
CILASTATIN SODIUM / IMIPENEM / RELEBACTAM, RECARBRIO, MSD MERCK CO
2029-07-16GAIN
2024-07-16NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Cilastatin Sodium / Imipenem / Relebactam, Recarbrio, Msd Merck Co
84870932029-11-19DS, DPU-2586, U-2587, U-2840
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DH: Carbapenems
— J01DH56: Imipenem, cilastatin and relebactam
HCPCS
Code
Description
J0742
Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg
Clinical
Clinical Trials
14 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bacterial pneumoniaD018410EFO_1001272J15.9——11—2
InfectionsD007239EFO_0000544———1—1
Gram-negative bacterial infectionsD016905———1—1
Critical illnessD016638———1—1
ObesityD009765EFO_0001073E66.9———1—1
Cystic fibrosisD003550EFO_0000390E84———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urinary tract infectionsD014552EFO_0003103N39.0—11——2
Intraabdominal infectionsD059413—11——2
Bacterial infectionsD001424A49——1——1
Ventilator-associated pneumoniaD053717EFO_1001865J95.851——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PyelonephritisD011704EFO_1001141N10-N16—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SepsisD018805A41.92————2
Communicable diseasesD0031411————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRELEBACTAM
INNrelebactam
Description
Relebactam is a chemical compound used in combination with antibiotics to improve their efficacy. As a beta-lactamase inhibitor, it blocks the ability of bacteria to break down a beta-lactam antibiotic. In the United States, relebactam is approved for use in the combination imipenem/cilastatin/relebactam (Recarbrio).
Classification
Small molecule
Drug classbeta-lactamase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O.O=C(NC1CCNCC1)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O
Identifiers
PDB—
CAS-ID1174018-99-5
RxCUI2184137
ChEMBL IDCHEMBL3301605
ChEBI ID—
PubChem CID44129647
DrugBankDB12377
UNII ID1OQF7TT3PF (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,193 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
8,049 adverse events reported
View more details